17649-86-4

Basic information

• Product Name: 3-Buten-2-one, 4,4-bis(methylthio)-
• CAS NO: 17649-86-4
• Molecular Formula: C6H10OS2
• Molecular Weight: 162.277
• Mol File: 17649-86-4.mol
• Article Data: 35

Chemical Properties

• CAS DataBase Reference: 3-Buten-2-one, 4,4-bis(methylthio)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Buten-2-one, 4,4-bis(methylthio)-(17649-86-4)
• EPA Substance Registry System: 3-Buten-2-one, 4,4-bis(methylthio)-(17649-86-4)

Safety Data

• Hazardous Substances Data: 17649-86-4(Hazardous Substances Data)

Upstream product

• 54893-95-7 ethyl 2-acetyl-3,3-bis(methylthio)acrylate 
• 5780-61-0 4,4-dichlorobut-3-en-2-one 
• 14527-26-5 2-methylisothiourea sulphate 
• 5188-07-8 sodium thiomethoxide 
• 75-15-0 carbon disulfide 
• 67-64-1 acetone 
• 74-88-4 methyl iodide 
• 865-47-4 potassium tert-butylate 
• 75-05-8 acetonitrile 
• 123-54-6 acetylacetone 
• 15908-50-6 3-[di(methylthio)methylene]pentane-2,4-dione 
• 624-92-0 Dimethyldisulphide 
• 560095-47-8 (3-buten-2-yl)pentamethyl phosphoric triamide 

Downstream Products

• 92807-28-8 5,5-Bis-methylmercapto-1-(4-methoxy-phenyl)-pentadien-1,4-on-3 
• 117671-88-2 2,6-Bis(methylthio)-4-hydroxyacetophenone 
• 117671-77-9 (Z)-3-Hydroxy-5,5-bis-methylsulfanyl-1-phenyl-penta-2,4-dien-1-one 
• 126978-95-8 1-(imidazolidin-2-ylidene)-propan-2-one 
• 143158-98-9 4,4-bis(methylthio)-1-(2-cyclohexenyl)-3-buten-2-one 
• 34047-39-7 4-methylsulfanyl-2-butanone 
• 78-93-3 butanone 
• 117672-15-8 (E)-1,1-bis (methylthio)-5-(3,4,5-trimethoxyphenyl)penta-1,4-dien-3-one 
• 1059605-43-4 3-(benzylthiomethyl)-4,4-bis(methylthio)but-3-en-2-one 
• 1493776-44-5 1-(5-(methylthio)-2-(trifluoromethyl)phenyl)propan-2-one 

Relevant articles and documents

Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27 - a transcriptionally repressive post-translational modification (PTM). EZH2 is commonly mutated in hematologic malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis. First generation EZH2 inhibitors are beginning to show clinical benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition. During our medicinal chemistry campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time. Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochemical properties, which have the potential to expand the clinical use of EZH2 inhibition.

EZH2 covalent irreversible inhibitor as well as preparation method and application thereof

The invention discloses an EZH2 covalent irreversible inhibitor as well as a preparation method and application thereof. The EZH2 covalent irreversible inhibitor comprises a compound with a structure as shown in a formula (I) or a formula (II) or a salt t

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositons thereof, which are useful for treating a variety of conditions associated with methyl modifying enzymes.